Eli Lilly will use the European Association for the Study of Diabetes 2026 meeting to detail Phase 3 retatrutide results, new Foundayo data and the first Phase 2 readout for eloraTZP, revealing how the company intends to segment an increasingly competitive obesity and diabetes market.
An NYU Langone study of more than 3.5 million children found rapidly increasing off-label GLP-1 prescribing below age 12, concentrated among children with severe obesity and related disease.
Eli Lilly and Company says one-year Phase 3b data from TOGETHER-PsO and TOGETHER-PsA show sustained or deeper improvements when Zepbound and Taltz are used together in patients living with psoriatic disease and obesity.
Eli Lilly and Company has created a limited expanded-access pathway for adults with severe, treatment-resistant obesity, even as regulators warn that products sold online as retatrutide are unapproved, potentially contaminated and illegal to compound.
Neurocrine Biosciences has initiated a first-in-human Phase 1 study of NBIP-1968, a once-weekly experimental obesity treatment designed to activate the GLP-1, GIP and glucagon receptors through a single molecule. The August 7, 2026 development marks Neurocrine Biosciences’ entry into clinical testing with an incretin-based obesity candidate. The study will initially examine single ascending doses in
See how Novellia’s GLP-1 registry could sharpen real-world evidence while facing tests on validation, bias, privacy and payer use.
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.